Compare GIXI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIXI | LGVN |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 7.8M |
| IPO Year | 2019 | 2021 |
| Metric | GIXI | LGVN |
|---|---|---|
| Price | $3.50 | $3.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | ★ 112.9K | 97.8K |
| Earning Date | 11-30-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | N/A | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.37 | $0.48 |
| 52 Week High | $8.34 | $7.60 |
| Indicator | GIXI | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 64.84 |
| Support Level | N/A | $0.63 |
| Resistance Level | $4.60 | $7.30 |
| Average True Range (ATR) | 0.26 | 0.24 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 8.85 | 84.44 |
Gix Internet Ltd provides infrastructure for managing and authorizing autonomous systems, including autonomous mobile robots (AMRs), automated guided vehicles (AGVs), humanoid robots, robotaxis, shuttles, drones, and human workforces. The company's platform provides: mission generation and orchestration across mixed-fleet environments; real-time authorization and policy-gate enforcement for regulatory compliance; and cryptographically signed records of authorized actions for regulatory compliance.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.